PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28403626-10 2019 In patients with ACS treated with aspirin and clopidogrel, residual platelet aggregation was significantly reduced 20 min after intravenous bolus of 1 mg/kg pegnivacogin (100% versus 43.21+-8.23%, p=0.020). Aspirin 34-41 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 17-20 30923029-0 2019 Omission of aspirin after ACS or stenting in patients with oral anticoagulation - why have the goalposts moved? Aspirin 12-19 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 26-29 25252038-6 2016 RESULTS: At univariate analysis, C2238/ANP-minor allele carrier status and treatment with beta-blocker, aspirin and statin were associated with risk of re-ACS. Aspirin 104-111 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 155-158 28975318-0 2017 In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events. Aspirin 35-42 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 15-18 28975318-0 2017 In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events. Aspirin 70-77 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 15-18 28540312-4 2017 We present a case in which a patient successfully underwent a 3-month course of rivaroxaban in addition to his dual antiplatelet regimen of aspirin and ticagrelor for his STE-ACS and LV thrombus with resultant complete dissolution. Aspirin 140-147 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 175-178 27548237-3 2016 A decision analysis model was constructed comparing three P2Y12 inhibitors in addition to aspirin in patients with NSTE-ACS. Aspirin 90-97 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 120-123 25440788-7 2014 Finally, the combination of aspirin, clopidogrel, and low-dose rivaroxaban has recently been approved by the European Medicines Agency (but not the Food and Drug Administration) for secondary prevention after ACS. Aspirin 28-35 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 209-212 25660936-0 2015 Reply: Triple therapy for atrial fibrillation and ACS with or without PCI: don"t drop aspirin just yet. Aspirin 86-93 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 50-53 27001784-1 2016 The purpose of the research is to give the effectiveness and safety of ticagrelor in combination with acetylsalicylic acid as preoperative treatment of primary stenting in patients with ACS. Aspirin 102-122 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 186-189 25293617-2 2014 The proven benefits of aspirin in preventing further thrombotic events in patients with prior ACS or stroke make it difficult to withdraw this therapy. Aspirin 23-30 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 94-97 25634391-1 2014 BACKGROUND: Clopidogrel has been the only available antiplatelet drug used along with aspirin in patients of ACS. Aspirin 86-93 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 109-112 23283029-3 2013 Hypothetically considering its antiaggregating and anti-inflammatory effects, aspirin might also be beneficial for the primary prevention of ACS in patients with pneumonia. Aspirin 78-85 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 141-144 23474908-12 2013 Hence, 12 months of ACS treatment using ticagrelor/ASA instead of clopidogrel/ASA may offer a cost-effective therapeutic option, even when the generic price for clopidogrel is employed. Aspirin 51-54 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 20-23 23283029-10 2013 RESULTS: The chi-test showed that the rates of ACS at 1 month were 1.1% (n=1) in the aspirin group and 10.6% (n=10) in the control group (relative risk, 0.103; 95% confidence interval 0.005-0.746; P=0.015). Aspirin 85-92 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 47-50 23283029-11 2013 Aspirin therapy was associated with a 9% absolute reduction in the risk for ACS. Aspirin 0-7 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 76-79 23283029-13 2013 CONCLUSION: This randomized open-label study shows that acetyl salicylic acid is beneficial in the reduction of ACS and cardiovascular mortality among patients with pneumonia. Aspirin 56-77 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 112-115 23404329-3 2013 Results demonstrated that low doses of ASP (1 mM), CUR (10 microM) and SFN (5 microM) (ACS) combination reduced cell viability by ~70% (P<0.001), and also induced cell apoptosis by ~51% (P<0.001) accompanied by activation of caspase-3 and Poly(ADP-ribose) polymerase (PARP) proteins. Aspirin 51-54 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 99-102 19890703-2 2009 DISCUSSION: The key role of platelet-mediated thrombosis in the pathogenesis of NSTE ACS is confirmed by the proven clinical benefits of antiplatelet agents (aspirin and a P2Y(12) adenosine diphosphate [ADP] receptor antagonist) in this setting. Aspirin 158-165 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 85-88 20223389-10 2010 Patients who received aspirin were more likely to be white (60% vs 54%, P = .0009) or have an ACS diagnosis (82% vs 50%, P < .0001). Aspirin 22-29 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 94-97 20223389-13 2010 CONCLUSION: For patients with undifferentiated chest pain, overall race, sex, and age differences were explained by higher rates of aspirin administered to older men with non-ACS chest pain. Aspirin 132-139 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 175-178 16771000-1 2006 INTRODUCTION: Aspirin is administered to patients with acute coronary syndromes (ACSs), but prehospital providers do not administer aspirin to all patients with chest pain that could be secondary to an ACS. Aspirin 14-21 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 81-84 19695356-4 2009 In this review, we highlight the relevant trial evidence for antiplatelet therapy (aspirin, P2Y(12) inhibitors, and small molecule glycoprotein IIb/IIIa inhibitors) in NSTE ACS in relation to age, taking into consideration the risks and benefits, dose, concomitant therapy, and duration of use. Aspirin 83-90 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 173-176 17580408-0 2007 Aspirin is lifesaving for cancer patients with ACS. Aspirin 0-7 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 47-50 17264949-3 2007 It was the aim of the present study to assess whether the response to aspirin and clopidogrel may be influenced by the 807 C/T polymorphism of the glycoprotein Ia (GpIa) gene in patients with non-ST elevation acute coronary syndrome (NSTE ACS). Aspirin 70-77 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 239-242 16894002-6 2006 Patients with ACS as the admission diagnosis more frequently received cardiac catheterization (during 2000-2001, 39% versus 17%, p < 0.001), percutaneous coronary intervention (19% versus 4%, p < 0.001), and evidence-based therapy; during 1998-2001, opportunities to give ASA or BB on admission were fulfilled for 88% versus 73% (p < 0.001), and on discharge, for 87% versus 74% (p < 0.005). Aspirin 278-281 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 14-17 15871650-0 2005 Value for money in disease management of acute coronary syndrome--the price of aspirin to reduce the costs of ACS. Aspirin 79-86 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 110-113 11871134-13 2002 In patients with high risk for coronary heart diseases, hsCRP-guided therapy is possible by using aspirin, stains, and antibiotics for prevention of ACS. Aspirin 98-105 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 149-152